Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260820 | 0.77 | KMT2A (0.61) | KMT2AALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL28137631 | 0.75 | KMT2A (0.59) | KMT2AALDH1A1MAPK1 | |
| SCHEMBL17086158 | 0.74 | NPC1 (0.44) | SMN1; SMN2NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL28745297 | 0.74 | S100A9 (0.31) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12474258 | 0.73 | AGXT (0.47) | KMT2A | |
| SCHEMBL17080246 | 0.72 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL22468699 | 0.71 | KDM4E (0.31) | KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL20364675 | 0.71 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL31328880 | 0.70 | MMP2 (0.39) | CYP11B1 | |
| SCHEMBL20508396 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| CN-106413402-B | Hepatitis b core protein allosteric modulators | 美国印第安纳大学研究和技术公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3607950-A2 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research & Technology Corporation (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3116316-B1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | UNIV INDIANA RES & TECH CORP (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10183936-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180273521-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research and Technology Corporationt (US) | 2018-09-27 | — | — | US | disclosed |
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-01-19 | — | — | US | disclosed |
| EP-3116316-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research And Technology Corporation (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015138895-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | SMN1; SMN2 4496/4885NPC1 953/4885NFKB1 1667/4885 |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | SMN1; SMN2 4496/4885NPC1 953/4885NFKB1 1667/4885 |
| US-20180273521-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | SMN1; SMN2 4496/4885NPC1 953/4885NFKB1 1667/4885 |
| US-10183936-B2 | Hepatitis B core protein allosteric modulators | HAVCR2, MAVS, FABP1 | SMN1; SMN2 4496/4885NPC1 953/4885NFKB1 1667/4885 |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | HAVCR2, MAVS, FABP1 | SMN1; SMN2 4496/4885NPC1 953/4885NFKB1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.